Straumann Holding AG (STMN) AI Stock Analysis

• Market Cap: CHF15.15B
• Dividend Yield: 1%
• Average Volume (3M): 415.23K
• Price to Earnings (P/E): 38.6
• Beta (1Y): 1.13
• Revenue Growth: 4.49%
• EPS Growth: 45.08%
• Country: CH
• Employees: 11,342
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): N/A
• Shares Outstanding: 159,455,250
• 10 Day Avg. Volume: 293,178
• 30 Day Avg. Volume: 415,225
• PEG Ratio: 0.80
• Price to Book (P/B): 8.93
• Price to Sales (P/S): 7.27
• P/FCF Ratio: 57.71
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF96.43
• Price Target Upside: 1.72% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 8
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 72 Outperform
• Price Target: CHF105.00 ▲(10.76% Upside)

Straumann Holding AG's overall stock score is driven by strong financial performance and positive earnings call highlights. However, technical indicators suggest potential bearish momentum, and the high P/E ratio indicates possible overvaluation. Challenges in China and currency impacts also weigh on the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business sustainability.

Strategic Partnerships

Strategic partnerships enhance product offerings and market position, driving innovation and competitive advantage in the orthodontic segment.

Digital Innovation

The new scanner strengthens Straumann's digital ecosystem, improving product integration and customer value, fostering long-term growth.

Negative Factors

Challenges in China

Regulatory changes in China pose significant challenges, potentially affecting revenue and market presence in a key growth region.

Currency Exchange Impact

Currency fluctuations can erode profitability and create financial uncertainty, impacting long-term financial performance.

Tariff Cost Pressure

Increased tariffs add to operational costs, potentially squeezing margins and affecting competitive pricing strategies.

Straumann Holding AG Business Overview & Revenue Model

Company Description

Straumann Holding AG is a global leader in dental implant and restorative solutions, specializing in innovative products and digital technology for dental professionals. Founded in 1954 and headquartered in Basel, Switzerland, the company operates primarily in the fields of implant dentistry, digital dentistry, and orthodontics. Its core offerings include dental implants, prosthetics, biomaterials, and digital solutions that enhance treatment outcomes and improve patient care.

How the Company Makes Money

Straumann generates revenue through multiple streams primarily centered around its dental implant and restoration products. The company earns money by selling dental implants, prosthetic components, and biomaterials to dental clinics and laboratories. In addition, it offers digital solutions, including software and equipment for dental imaging and planning, which further diversifies its revenue. Significant partnerships with dental professionals and institutions help drive sales, while a focus on research and development ensures a steady pipeline of innovative products that meet evolving market demands. The company also benefits from recurring revenue through consumables used in dental procedures, contributing to consistent earnings growth.

Straumann Holding AG Financial Statement Overview

Summary

Straumann Holding AG shows strong financial performance with consistent revenue growth and a healthy balance sheet. However, rising operational costs and liabilities need attention.

Income Statement

Straumann Holding AG has demonstrated consistent revenue growth with a solid increase from 2023 to 2024. Gross Profit Margin is strong, indicating effective cost management. However, there is a slight decline in EBIT and EBITDA margins, suggesting rising operating costs or increased competition.

Balance Sheet

The company's balance sheet is stable with a moderate Debt-to-Equity ratio, reflecting balanced leverage. The Return on Equity is healthy, indicating efficient use of equity. The Equity Ratio is solid, showing a strong financial position, although the increase in total liabilities warrants monitoring.

Cash Flow

The cash flow is robust with a stable Free Cash Flow, reflecting the company's good cash generation capacity. There is a slight decline in Operating Cash Flow, which could be a sign of higher operational expenses. The Free Cash Flow to Net Income ratio is favorable, indicating efficient cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.58B	2.50B	2.41B	2.32B	2.02B	1.43B
Gross Profit	1.83B	1.78B	1.79B	1.70B	1.53B	1.03B
EBITDA	850.33M	726.15M	495.42M	678.33M	591.48M	230.45M
Net Income	392.72M	388.32M	246.07M	434.79M	396.08M	91.28M
Balance Sheet
Total Assets	3.51B	3.62B	3.40B	3.45B	3.05B	2.62B
Cash, Cash Equivalents and Short-Term Investments	246.53M	383.07M	413.54M	697.11M	881.50M	632.49M
Total Debt	411.27M	460.90M	412.35M	705.20M	711.66M	731.66M
Total Liabilities	1.45B	1.58B	1.56B	1.60B	1.55B	1.41B
Stockholders Equity	2.06B	2.04B	1.84B	1.85B	1.50B	1.20B
Cash Flow
Free Cash Flow	351.32M	315.62M	316.61M	220.94M	440.97M	295.34M
Operating Cash Flow	500.77M	483.39M	503.95M	416.38M	561.94M	377.41M
Investing Cash Flow	-392.95M	-352.62M	-349.33M	-449.84M	-185.20M	-145.64M
Financing Cash Flow	-180.68M	-169.06M	-424.40M	-140.35M	-122.90M	153.33M

Straumann Holding AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 94.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:STMN, the sentiment is Positive. The current price of 94.8 is above the 20-day moving average (MA) of 93.95, above the 50-day MA of 93.69, and below the 200-day MA of 100.01, indicating a neutral trend. The MACD of -0.18 indicates Negative momentum. The RSI at 52.57 is Neutral, neither overbought nor oversold. The STOCH value of 83.32 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:STMN.

Straumann Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALC	75 Outperform	CHF31.22B	34.38	4.82%	0.44%	0.39%	-12.46%
STMN	72 Outperform	CHF15.15B	38.57	―	1.00%	4.49%	45.08%
GALD	70 Outperform	CHF38.04B	117.25	―	0.09%	6.22%	―
SOON	68 Neutral	CHF11.91B	23.71	―	2.13%	3.79%	-7.84%
MED	62 Neutral	CHF1.15B	-2,191.33	―	―	7.29%	-112.70%
SKAN	55 Neutral	CHF1.10B	68.03	―	0.82%	-3.45%	-49.82%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Straumann Holding AG Corporate Events

Straumann Holding AG Unveils Growth Strategy for 2030

Straumann Holding AG has unveiled its medium-term growth strategy aimed at increasing market share, profitability, and cash flow by 2030. The company plans to leverage its digital platform, Straumann AXS, to enhance treatment predictability and efficiency, thereby improving clinical outcomes. By expanding its digital solutions and innovation pipeline, Straumann aims to strengthen its leadership in implantology and make significant strides in orthodontics and prosthetics. The strategy also emphasizes a high-performance culture and targeted investments to drive sustainable growth and stakeholder value.

Straumann Group to Unveil Future Strategy at Capital Markets Day 2025

Straumann Group has announced its Capital Markets Day 2025, scheduled for November 25, 2025, where it will review past achievements and outline its future strategy and growth objectives. The event will address the evolving market dynamics and trends influencing the dental industry, highlighting the company’s transformation efforts and strategic direction.

Straumann Group Reports Strong Q3 Growth and Confirms 2025 Outlook

Straumann Group reported strong organic growth of 8.3% in the third quarter of 2025, with revenue reaching CHF 602.2 million. The company confirmed its outlook for 2025, aiming for high single-digit organic revenue growth despite tariff impacts. Key growth regions included EMEA and Latin America, while North America showed improvement and Asia-Pacific faced challenges in China. Strategic partnerships in orthodontics and the launch of the SIRIOS X3 intraoral scanner are expected to enhance innovation and market positioning.

Straumann Group Transforms Orthodontics Business with Strategic Partnerships

Straumann Group has announced new strategic partnerships to transform its orthodontics business, focusing on innovation, key markets, and operational excellence. By partnering with Smartee and DentalMonitoring, Straumann aims to enhance its ClearCorrect brand’s positioning, improve efficiency, and increase profitability, thereby strengthening its competitiveness in the global orthodontics market.